The demonstration of cardiorenal benefits with SGLT2i in clinical trials both for participants with CKD and type 2 diabetes and for those without [23,24,25] and the updated 2022 KDIGO guidelines recommending SGLT2i as first-line therapy for patients with CKD and type 2 diabetes regardless of glycemic control [6] have likely driven a shift toward their broader use for preventive cardiorenal protection and earlier implementation for patients with type 2 diabetes
More data show GLP-1s may reduce addiction risk
Wang et al., 2008b)
In 2 randomized controlled trials conducted by Xu et al, 24,25 the administration of vitamin B12 in varying forms in patients with postherpetic neuralgia and acute ophthalmic herpetic neuralgia sustainably and significantly decreased their pain severity for up to 1 year compared with controls receiving intramuscular injection of vitamin B12 and lidocaine
A Vegas breakfast buffet inside each patch I found 11 studies of LifeWaves products, with the earliest dating back to 2005, and what struck me were the conflicted explanations of how the famed patch was supposed to work, akin to the parable of the blind men and the elephant
The latest GLP-1 coverage expansion and AI initiatives support the existing narrative but do not materially change these near term drivers
